Radiation Quality and Workflow in NRG GY017: Anti PD-L1 (Atezolizumab) as an immune primer or concurrently with RT for node positive locally advanced cervical cancer
{{output}}
Objectives: Advances in radiation (RT) treatment planning enhance the need for uniform quality oversight on clinical trials. NRG GY-017 was a randomized trial of the anti PD-L1 antibody, atezolizumab, before and concurrent (Arm A... ...
